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The recent article from Dr Frevert of Merz,[1]
together with the accompanying commentary from
Dr Sesardic of NIBSC,[2] makes a new contribution
to the data available for clinical botulinum toxin
type A (BoNT-A) products. However, in addition
to the comments about the various technical as-
pects of the data provided by Dr Frevert, as de-
scribed by Dr Sesardic,[2] one important and key
factor about the BoNT-A products has not been
mentioned. The units of each product are differ-
ent, not interchangeable, and no fixed or estab-
lished conversion ratio exists between them,[3-5]
regardless of what clinical data are presented.
This means that any data trying to represent
the biochemical characteristics of the products
in relation to their potency units, and then com-
paring them with each other, is potentially mis-
leading to the reader. The data included in the
article, giving the amount of BoNT-A neurotoxin
per 100 LD50 (median dose that is lethal to 50%
of animals tested) units of potency, is therefore
incorrect as a comparison.[1] It is inappropriate to
provide such data as readers may draw erroneous
(and potentially dangerous) conclusions without
a detailed interpretation. Product comparisons
based on these data should not be made. Dr Frevert
has not informed the reader that the potency
units of each product are specific to that product.
Quite the contrary – he has attempted to show
that 1 unit of Xeomin is equivalent to 1 unit of
Botox, which is against the regulatory require-
ments for the products, as stated in their product
characteristics.[4-5]
True, there is a new statement in the product
characteristics for the Merz low-dose product
Bocouture,[6] which states ‘‘Comparative clin-
ical study results suggest that Bocouture and the
comparator product containing conventional
Botulinum toxin type A complex (900 kD) are
of equal potency.’’ However, immediately above
this in the document is the standard statement (in
bold) that reads ‘‘Unit doses recommended for
Bocouture are not interchangeable with those for
other preparations of Botulinum toxin.’’
Dr Frevert has also commented that all three
of the main BoNT-A products are made from the
same Hall strain of bacteria. In fact, there is no
evidence yet published to support this. Quite the
contrary – latest data indicate that the so-called
Hall strains are different to each other.[7,8] As
previously described, there are several so-called
Hall strains and they are different.[7] The Aller-
gan strain information is published[9] and the
Ipsen and Merz strains have only been described
as ‘Hall strain’, with no identification.[1,10]
As written several times before, certain data
claimed for Dysport (the size of the BoNT-A
complex, for example), have never been published.
The early reference from 1992 cited by Dr Frevert
is incorrect for Dysport. However, Dysport is
the only commercial BoNT-A product for which
detailed biochemical characterization data have
been published, notably on composition.[10]We have
challenged colleagues in the other manufacturers
to publish their own, similar data, but to date they
have declined. This is somewhat extraordinary for
products that have been available commercially,
for many years.
Dr Frevert once again discusses BoNT-A com-
plexes and their respective so-called ‘sizes’ for the
products.[1] We have published about this mis-
leading subject on several occasions.[11-13] From
his own data, Dr Frevert has already demon-
strated that the ‘size’ of the toxin complex is ir-
relevant to the biological actions.[14] Indeed, the
very latest data from Merz,[15] published after Dr
Frevert’s article, appear to now clarify this sub-
ject. The BoNT-A neurotoxin molecules are free
in the vial after reconstitution and not associated
with the complex. These are the only data rele-
vant to the discussion on the ‘size’ of the BoNT-A
complex and use of the clinical products – the
complex size itself appears to be irrelevant. BoNT
scientists had expected this finding, but proof was
needed; it now exists.
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The purpose of Dr Frevert’s article was to
compare the neurotoxin content of each of the
BoNT-A products in the vial.[1] A new figure has
now appeared for Xeomin, 0.44 ng per vial, as
compared to the 0.6 ng previously published.[16]
This finding is somewhat dismissed as a technical
issue but, in reality, represents a 27% reduction.
Could this be due to changes in the product since
the data were first reported or the product first
used (perhaps changes in batches of active com-
ponent, for example, see Quarta[17] or other issues)?
Whatever the cause, this significant difference is
a product inconsistency that warranted further
comment, representing an important aspect of the
work to the clinicians – consistent product gives
consistent clinical results.
Data comparing the characteristics of the vari-
ous BoNT-A products andmisleadingly comparing
these to labeled units are not helping clinicians se-
lect products for use. Instead, detailed overall data,
notably on history of product consistency, such as
those previously published for Dysport,[10] are
important for clinicians and these are still awaited
for the other BoNT-A products. Perhaps the time
has also come to stop discussing BoNT-A complex
‘sizes’ in a clinical context unless and until data are
produced that clearly demonstrate any relevance to
clinical use? None now seem likely.
Andy Pickett
Toxin Science Limited, Wrexham, UK
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Author’s Reply
The main focus of the letter to the editor by
Dr Pickett[1] is the interchangeability of botulinum
toxin A dosages between products, and therefore
this answer will address this issue.
In contrast to the argument of Dr Pickett, it is
justified to draw conclusions on botulinum toxin
A products based on the potency. It is true that
the units of each product are determined by dif-
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